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Abstract There are a number of imaging tests that
are used in the setting of acute myocardial infarction
and acute coronary syndrome. Each has their
strengths and limitations. Experts from the European
Society of Cardiac Radiology and the North
American Society for Cardiovascular Imaging
together with other prominent imagers reviewed the
literature. It is clear that there is a deﬁnite role for
imaging in these patients. While comparative accu-
racy, convenience and cost have largely guided test
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Introduction
In order to improve the accuracy of the diagnosis of
myocardial infarction (MI) for clinicians and clinical
scientists, multinational task forces met in 1999–2000
under the auspices of the European Society of
Cardiology (ESC), the American College of Cardiol-
ogy Foundation (ACCF), the American Heart Asso-
ciation (AHA), and the World Heart Federation
(WHF) in order to develop a simple, clinically
oriented, universal deﬁnition for MI that could be
employed both in daily clinical practice and in clinical
investigation. The report of the original task force was
published simultaneously in the European Heart
Journal and the Journal of the American College of
Cardiology in 2000 [1, 2] and later updated by a joint
ESC/ACCF/AHA/WHF task force [3–5].
A consensus report the British Cardiovascular
Society developed the deﬁnition into three clinical
categories [6] (a) Acute Coronary Syndrome (ACS)
with clinical myocardial infarction in which there
is a raised troponin greater than 1 ng/ml± raised
CK-MB or AccuTn1 greater than 0.5 ng/ml. These
patients usually have a complete coronary occlusion,
evidence of left ventricular dysfunction and ECG
changes of ST elevation, ST depression, or T wave
inversion and the risk of death in this syndrome is
12–15%. (b) The patient may have an acute
coronary syndrome with myocardial necrosis in
which case the troponin although elevated is less
than 1 ng/ml. The patient usually has intracoronary
thrombus and some evidence of left ventricular
dysfunction, the risk of death in this intermediate
state is 8–12%. The third syndrome is (c) acute
coronary syndrome with unstable angina. In this
syndrome the troponin and/or other biomarkers are
not raised and the ECG changes of ST depression or
elevation may be transient. This syndrome has a
reduced risk of death and usually is not associated
with left ventricular dysfunction. Coronary plaque
disruption and partial coronary occlusion may be
present.
After the onset of insufﬁcient myocardial oxygn-
eation, it takes several hours before larger amounts of
cell death occur and myocardial necrosis can be
identiﬁed by macroscopic or microscopic post-mor-
tem examination. Complete necrosis of all myocar-
dial cells within the area at risk requires at least 2–4 h
or longer depending on the presence of collateral
circulation to the ischemic zone, persistent or inter-
mittent coronary arterial occlusion, the sensitivity of
the myocytes to ischemia, pre-conditioning, and/or,
ﬁnally, individual demand for myocardial oxygen and
nutrients. However, in terms of clinical therapy it is
essential that the diagnosis of an acute coronary
syndrome should be established quickly and accu-
rately as therapy has to be instigated to limit
myocardial necrosis. The concepts of ‘door to needle
time’ for thrombolysis and ‘door to balloon time’
have been established for primary percutaneous
coronary artery interventions (PCI) [7].
In patients presenting with acute myocardial
infarction (AMI) present with ST elevation (STEMI)
[8], delays in primary PCI increase mortality. The
tight window for STEMI allows very little time for
additional diagnostic steps including imaging with
the exception of the pre PCI coronary angiogram and
an emergency room diagnostic cardiac ultrasound.
Myocardial infarction without ST elevation pre-
sents a different clinical situation. It is essential that
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123the diagnosis is established correctly in order that
appropriate treatment can be commenced. In these
acute cases the ECG changes may include left bundle
branch block or signs of ischemia on the ECG.
Myocardial infarction may be ‘‘silent.’’ In the
Framingham study, over 30 years 1 in 4 myocardial
infarcts were detected because of routine biannual
ECG examinations [9] and several recent magnetic
resonance trials have demonstrated a signiﬁcant
proportion of unrecognized myocardial infarction.
Patients may also present atypically whilst undergo-
ing myocardial infarction and in these cases imaging
may play a signiﬁcant role.
Myocardial infarctions are usually classiﬁed by
size: microscopic (focal necrosis), small (\10% of
the left ventricular myocardium),moderate (10–30%
of the LV myocardium), and large ([30% of the LV
myocardium), and by location [6]. The pathological
identiﬁcation of myocardial necrosis is made without
reference to morphological changes in the coronary
arterial tree or to the clinical history.
The ‘‘universal’’ deﬁnition of myocardial infarc-
tion of the ESC/ACCF/AHA/WHF task force
included the use of imaging tests and cardiac
biomarkers [3–5]. The imaging evidence of a new
loss of myocardium or new regional wall motion
abnormality is now a key part of the deﬁnition of
myocardial infarction. This widened deﬁnition offers
the opportunity for the use of a range of imaging
tests. This paper from the European Society of
Cardiac Radiology and the North American Society
for Cardiovascular Imaging aims to discuss the use
and context of these tests in the diagnosis of acute
myocardial infarction and to widen the guidelines for
imaging in the light of these new developments.
Physiologic assessment of myocardial infarction
ECG
ST elevation myocardial infarction (STEMI)
Myocardial infarction is stratiﬁed according to the
presence or absence of elevation of the ST-segment.
The presence of ST-segment elevation denotes total
occlusion of a coronary artery and identiﬁes patients
who would beneﬁt from reperfusion therapy, either
with the administration of thrombolytic agents or
preferably by primary percutaneous coronary inter-
vention [10].
By deﬁnition, in order to diagnose a STEMI, ST-
segment elevation of greater than 0.1 mV should be
present in at least two contiguous limb or precordial
leads, with the exclusion of aVR, which ‘‘sees’’ the
left ventricular cavity. However, in leads V1–V4, a
higher ST-segment elevation of greater than 0.2 mV
has greater speciﬁcity and diagnostic accuracy. There
are two situations where there is total occlusion of an
artery causing an AMI, and would beneﬁt from early
reperfusion therapy, in which ST-segment elevation
may not be present in the 12-lead ECG; AMI of the
posterior wall and the new presence of left bundle
branch block (LBBB). True posterior AMI is sus-
pected when there is marked ST-segment depression
in leads V1–V4 along with tall R waves and upright T
waves in right precordial leads. In these cases,
posterior leads V7 and V8 should demonstrate ST-
segment elevation and lead to the correct diagnosis.
Patients with new or presumably new LBBB caused
by AMI are at high risk; however, the presence of
LBBB may lead to delays in diagnosis and manage-
ment. Three characteristics have been associated with
new MI in the presence of LBBB, and, when present,
prompt for urgent management; ST elevation greater
than or equal to 0.1 mV in leads with a positive QRS,
ST depression greater than or equal to 0.1 mV in V1–
V3, and ST elevation greater than or equal to 0.5 mV
in leads with a negative QRS [11].
It should be mentioned that in the hyperacute
phase (during the ﬁrst 2–30 min) of an AMI the ECG
may occasionally demonstrate hyperacute T waves
instead of ST-segment elevation. These T waves
should be distinguished from the peaked T waves
caused by hyperkalemia. Furthermore, it should be
emphasized that the presence of ST-segment eleva-
tion does not necessarily denote myocardial infarc-
tion. Over 90% of healthy young men have at least
0.1 mV of ST-segment elevation in at least one
precordial lead, a normal ﬁnding designed as a male
pattern [12]. This prevalence declines with age,
reaching 30% in men 76 years of age or older. Other
ECG mimics of acute myocardial infarction include
early repolarization, acute pericarditis, myocarditis,
hyperkalemia, Brugada syndrome, paced rhythm,
apical left ventricular ballooning syndrome, and left
ventricular aneurysm. The presence of reciprocal
changes on the 12 lead ECG may help distinguish
Int J Cardiovasc Imaging (2011) 27:7–24 9
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acute myocardial infarction. The contour of the ST
segment may also be helpful, with a straight or
upwardly convex (non-concave) ST segment favour-
ing the diagnosis of acute myocardial infarction.
Estimation of infarct size and reperfusion therapy
The ECG may be helpful in the estimation of size of
myocardium at risk for necrosis. The number of leads
showing ST-segment deviation (elevation or depres-
sion) and the magnitude of the ST-segment deviation
are associated with the size of the ischemic myocar-
dium and with prognosis. The ﬁnal infarct size,
however, also depends on the timing and the efﬁcacy
of the reperfusion therapy. ECG has been for long
used to assess the efﬁcacy of reperfusion. The extent
of resolution of ST-segment elevation is a marker of
successful reperfusion either with thrombolytics or
with percutaneous coronary intervention [13]. This
has been demonstrated using various imaging tech-
niques, including contrast echocardiography [14],
radioisotope scintigraphy [15], and magnetic reso-
nance imaging [16]. Resolution of ST-segment ele-
vation after reperfusion therapy is associated with
less infarct size and better outcome.
Non-ST elevation acute coronary syndromes (ACS)
and unstable angina
The initial ECG in unstable angina (UA)/non-ST
elevation myocardial infarction (NSTEMI) may dem-
onstrate ST-segment depression and/or T wave inver-
sion. The presence of transient ST-segment
depression of at least 0.05 mV during an episode of
chest pain is strongly suggestive of acute ischemia.
The differential diagnosis of NSTEMI over UA,
however, can not be made until an elevation of cardiac
biomarkers is observed. The absence of ECG changes
does not preclude the diagnosis of ACS, since 1–6%
of patients with chest pain will ultimately be found to
have NSTEMI and at least 4% to have UA [17]. The
usually transient presence of ECG abnormalities
makes the serial ECG assessment essential in identi-
fying possible ACS patients. Furthermore, the com-
parison of the ECG during the acute episode with an
older one helps in the diagnosis.
The number of leads showing ST-segment depres-
sionandthemagnitudeofST-segmentdepressionmay
be a sign of extend of ischemia and provide important
prognostic information independent of other predic-
tors, such as clinical markers and cardiac biomarkers.
The presence of ST-segment depression in at least 3
ECG leads and maximal ST-segment depression of at
least 0.2 mV in patients with chest pain is associated
with greater likelihood of NSTEMI [18]. Furthermore,
the presence of ST-segment deviation is associated
with poorer prognosis than isolated T-wave changes
[19]. The presence of greater than or equal to 0.2 mV
symmetrical precordialT-waveinversionisassociated
to acute ischemia due to a critical stenosis of the left
anterior descending coronary artery (LAD) and it is
associated with poor prognosis [20]. NSTEMI that is
associated with the above changes will usually be
caused by thrombus in a coronary artery, which may
unlike a STEMI not be totally occlusive.
Cardiac biomarkers
For patients with a moderate or high probability of
ACS, physicians usually perform assays of markers
of myocardial injury such as the cardiac troponins T
or I (cTnT or cTnI) or creatinekinase—MB [3, 21].
The ideal serum marker for myocardial injury would
be speciﬁc to myocardium, highly sensitive and
quantitative with rapidly increased serum levels for
early diagnosis. Troponins now are the ‘gold stan-
dard’ method for diagnosis of myocardial infarction
[20–23]. Cardiac troponin I and troponin T are
proteins that regulate the calcium-dependent interac-
tions between actin and myosin and have been shown
to be very sensitive and speciﬁc markers of myocar-
dial cell injury. Different genes encode troponins T
and I in cardiac muscle, slow skeletal muscle, and
fast skeletal muscle; hence, the assays for cardiac
troponins are more speciﬁc than CK-MB for myo-
cardial injury. They start to rise approximately 4–6 h
after the onset of ACS and peak at approximately
24 h. Troponin measurements remain elevated for
7–14 days after the onset of the pain, giving long
diagnostic window. An increased value of elevated
troponin is assessed as a measurement exceeding the
99th percentile of a normal speciﬁcity for AMI. In
addition, troponin I provides a higher degree of test
speciﬁcity than troponin T. Blood samples should be
taken on the ﬁrst hours of the pain onset, 6–9 h later
and another sample between 12 and 24 h if the
previous measurements were not elevated but the
10 Int J Cardiovasc Imaging (2011) 27:7–24
123clinical suspicion was high [21]. Even low-level
increases of cardiac troponin are associated with an
increased rate of recurrent cardiovascular events.
Catheter based angiography
With the rapid development of primary angioplasty
catheter angiography and percutaneous intervention
have become central to the diagnostic and treatment
of myocardial infarction. Primary PCI (percutaneous
coronary intervention) is superior to ﬁbrinolytic
therapy in reducing the rates of death, reinfarction,
intracranial bleeding, reocclusion of the infarct
artery, and recurrent ischemia (even when inter-
hospital transport to a PCI-capable center is
required) when performed in a timely fashion by
experienced centres [24–30]. If a primary angio-
plasty protocol is being followed after an ECG
based diagnosis of STEMI, the patient is transferred
within the door-to-balloon time to a cardiac catheter
laboratory. Imaging studies after PCI for STEMI
have the possibility of adding value by deﬁning risk
stratiﬁcation. The feasibility and safety of perform-
ing cardiac magnetic resonance (CMR) in the
hyperacute phase of STEMI was recently veriﬁed
in a series of 64 patients after PPCI (primary
percutaneous coronary intervention)[31].
If primary angioplasty is not available, thrombol-
ysis is the next treatment of choice following which
if there is incomplete resolution of the chest pain
and ECG changes, ‘rescue angioplasty’ is often
undertaken. On a world wide basis ﬁbrinolytic
therapy is the most common treatment for STEMI
[26]. However, approximately 20% of patients who
suffer STEMI are not suitable for thrombolysis.
Many of these patients, however, do not have access
to coronary angioplasty.
There are two general exceptions to the rule that
patients who suffer STEMI should undergo primary
PCI as the preferred option. These are: (1) patients
with STEMI presenting greater than 12 h from
symptom onset without ongoing symptoms of ische-
mia or clinical instability; and (2) after successful
treatment of the culprit artery by PCI or ﬁbrinolysis,
revascularization of non-culprit arteries before hos-
pital discharge in patients without clinical instability,
with no evidence of recurrent or provokable ische-
mia, and with a normal LVEF [32]. There is almost
certainly a role for non-invasive imaging in these
groups of patients who either do not require or do not
have access to PCI and catheter angiography.
If the patient suffers a NSTEMI, the patient may
also be transferred acutely to the catheter lab as
myocardial necrosis also occurs in this condition. The
catheter lab therapy follows similar protocols to the
treatment of STEMI. Infarct size as measured by
acute CMR techniques has been found to smaller in
NSTEMI than STEMI [33].
SPECT imaging
Myocardial perfusion imaging in acute coronary
syndrome
Rest Tc-99 m sestamibi myocardial perfusion single
photon emission computed tomography (SPECT) has
been used to exclude acute coronary syndrome in ED
patients presenting with chest pain syndrome [34–
41]. The negative predictive value of acute rest
myocardial perfusion SPECT for ruling out myocar-
dial infarction in the ED is greater than 99% [34–36,
39, 41]. Kontos et al. [37] studied patients who
presented to the ED within 6 h of symptoms. Only
two of 361 patients (0.6%) with a negative test had an
acute myocardial infarction within 5 days of admis-
sion. Heller et al. [34] showed that only 2 of 204
patients (1%) with normal images had an acute
myocardial infarction during hospitalization in a
study involving 6 centers. The negative predictive
value of acute rest myocardial perfusion SPECT for
future adverse cardiac events is greater than 97% [34,
39–41]. Udelson et al. [40] prospectively evaluated
1,215 ED patients of 7 different hospitals who were
injected with Tc-99 m sestamibi during or within 3 h
of last chest pain episode.
Acute rest myocardial perfusion SPECT has also
been shown to reduce health care costs and length of
hospital stay in two randomized studies [38, 40].
Stowers et al. reported a median hospital costs of
$1,843 less for patients in the imaging-guided arm, in
whichtheSPECTimagingresultswereavailabletothe
ED physician. A prospective, randomized study [40]
(ERASE Chest Pain) conducted in 7 institutions
enrolled 2,475 ED patients who were randomized to
either routinemanagement intheEDoramanagement
strategy that included acute rest myocardial perfusion
SPECT. Hospitalization was reduced from 52% with
Int J Cardiovasc Imaging (2011) 27:7–24 11
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guided strategy.
Logistic hurdles have constrained the widespread
use of acute rest myocardial perfusion SPECT. The
radiotracer injection should take place during symp-
toms or within few hours of the last chest pain
episode for optimal diagnostic value of the test. There
should be around the clock availability of the
radiopharmaceutical and radiation safety trained staff
in the ED. Patients with a previous history of
myocardial infarction or coronary intervention are
not good candidates for acute rest myocardial perfu-
sion SPECT because a perfusion defect, if present,
may represent an old myocardial infarction.
The INSPIRE study was a prospective multi-
national clinical trial [42–44] designed to evaluate the
role of myocardial perfusion SPECT as a risk
assessment tool in stable patients within 10 days
after acute myocardial infarction. One-day nitrate-
enhanced rest and adenosine stress myocardial per-
fusion SPECT was performed in 728 patients with
either ST-elevation or non-ST-elevation myocardial
infarction. The INSPIRE trial demonstrated that
coronary angiography can be safely avoided in stable
acute myocardial infarction patients with small
(\20%) total defect size, minimal ischemia (\10%),
and preserved LV function. These patients had a low
(\2%) death/reinfarction event rate at considerably
lower associated costs and shorter length of hospital
stay compared with the higher-risk patients.
Rb-82 PET/CT in the assessment of myocardial
infarction
Hospitals with chest pain observation units have
developed alternative methods to triage chest pain
patients. After myocardial infarction has been
excluded by ECG and biomarkers, stress or rest/
stress myocardial perfusion imaging is performed. A
complete rest/stress imaging protocol is best used in
patients with a previous history of myocardial
infarction and/or revascularization. Rubidium myo-
cardial perfusion positron emission tomography
(PET) is an attractive approach in chest pain unit
patients. Rubidium is always available because in
contrast to other PET perfusion tracers (such as N-13
ammonia and O-15 water) that require an in-house
cyclotron for production, rubidium is generator
produced. Overall rubidium PET allows better
diagnostic accuracy and higher patient throughput
when compared to any SPECT protocol.
In a retrospective study 1,177 patients who
presented with chest pain to the ED were referred
for rest/stress rubidium myocardial perfusion PET
[45]. Of the 1,177 patients, 95.4% had normal images
and 4.6% had abnormal images. Of the abnormal
group, 52% had obstructive CAD at coronary arte-
riography while 41% were deemed to have ACS by
clinical assessment.
Ischemic memory imaging in acute coronary
syndrome
Following an ischemic episode, restoration of coro-
nary blood ﬂow precedes normalization of myocar-
dial metabolism by many hours. This process of
metabolic alteration is described as ischemic memory
or metabolic stunning. Metabolically stunned myo-
cardium preferentially uses glucose rather than free
fatty acids as its primary source of energy. This
metabolic phase can be used to evaluate patients in
whom the chest pain has subsided upon arrival to the
ED. Radioactive glucose (FDG) imaging demon-
strates selective tracer uptake in stunned myocardium
if the patient is injected at a fasting state [46–48].
Ischemic memory imaging has also been tested with
I-123 BMIPP, a free fatty acid analogue [49]. I-123
BMIPP SPECT images are the mirror images of
FDG: normal myocardium concentrates I-123 BMIPP
whereas stunned myocardium does not.
Two clinical studies by Kawai et al. [50, 51] have
shown the potential use of I-123 BMIPP ischemic
memory imaging in the ED. The ﬁrst report [51]
included a total of 111 patients who presented with
acute coronary syndrome. All patients underwent I-
123 BMIPP SPECT and coronary angiography within
one to 4 days. The sensitivity for obstructive coro-
nary disease or spasm at angiography was 74% and
the speciﬁcity was 92%. An ongoing clinical trial in
the United States will better deﬁne the value of I-123
BMIPP in ED patients.
Echocardiography
Each year in the United States, about 4 million people
undergo evaluation at the Emergency Department for
acute chest pain and more than 50% are admitted to
the hospital. Accurate evaluation of patients with
12 Int J Cardiovasc Imaging (2011) 27:7–24
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no elevation of serum levels of cardiac enzymes is
difﬁcult because of the low speciﬁcity of clinical
variables [52–54]. Echocardiography is used not only
to triage patients with suspected myocardial infarc-
tion, but it is also used in the acute phase of
myocardial infarction (MI) as a diagnostic and
prognostic tool.
Evaluation of patients with acute chest pain in the
emergency room comprises a frequent and sometimes
difﬁcult to resolve problem. Echocardiography has an
important role in establishing the diagnosis, location,
and extent of AMI, diagnosing possible associated
mechanical complications of the AMI, and can
provide prognostic information that is important for
risk stratiﬁcation. The American Heart Association,
and the American Society of Echocardiography
(ACC/AHA/ASE) gave a class I recommendation to
the use of echocardiography in the diagnosis of
suspected acute ischemia or infarction not evident by
standard means [55].
Echocardiographic changes in AMI, occur before
the onset of electrocardiographic changes or the
development of symptoms. Within seconds from the
occlusion of the coronary artery, severe ischemia
produces regional wall motion abnormalities that can
be visualized by cardiac ultrasound [56]. Furthermore
the effects of the acute myocardial injury in the
diastolic function of the left ventricle are important
and can be determined by Echocardiography. Echo-
cardiography can determine the location and extent of
the AMI, can access the left ventricular segments
involved, the severity of the wall motion abnormality
of the segments involved, calculate the wall motion
score index (WMSI) and can detect possible mechan-
ical complications.
The availability and use of echo-contrast agents
have resulted in better left ventricular opaciﬁcation
and better visualization of the left ventricular endo-
cardium making it easier to access segmental wall
motion abnormalities as well as with special protocols
visualize myocardial perfusion. The use of contrast
has expanded the capability of conventional 2D
echocardiography in the assessment of left ventricular
function. Echocardiography is very helpful in deter-
mining the presence or not of a thrombus in the left
ventricle and makes it easier to differentiate the
thrombus from an artifact or trabeculations especially
in dealing with difﬁcult images. Myocardial contrast
echocardiography (MCE) correlates with angio-
graphic methods of perfusion assessment such as
myocardial blush grade after thrombolysis [57].
After acute myocardial infarction, low dose dobu-
tamine stress echo can be performed safely in
stabilized patients who did not undergo coronary
revascularization—under some strict indications:
electrical stability, absence of symptoms, no signs
of severe cardiac failure, negative enzymes—in order
to assess risk stratiﬁcation, global and regional
ventricular function and the presence and extent of
residual myocardial ischemia. Especially in patients
with low EF due to ischemic cardiomyopathy dobu-
tamine stress echocardiography (DSE) can predict
cardiac death, a strong end point in patients who did
not undergo early revascularization [58, 59]. DSE can
also localize restenosis or graft occlusion and assess
adequacy of revascularization after acute coronary
syndrome [59–61].
The extent of myocardium at risk, affects the
beneﬁt from reperfusion strategies. In the presence of
transmural acute myocardial infarction (ST elevation
AMI), cardiac echo will show akinesia or dyskinesia
of the myocardial segments, and early reperfusion
may lead to the reversal of this effect. Sequential
echocardiograhic examinations have shown that the
improvement of the myocardial contraction is visible
within 24–48 h from reperfusion therapy if the
reperfusion is performed early after the event. The
persistent akinesia does not indicate failure of
thrombolysis. If the reperfusion therapy does not
achieve perfusion of[75% of the transmural thick-
ness of the myocardial wall, the myocardial segments
may remain akinetic. In case that akinesia remains
but viability exists, low dose dobutamine stress echo
(DSE) will result in a biphasic response with increase
in contractility of the previously akinetic myocardial
segment with low dose dobutamine. In case of
absence of viability, low dose of dobutamine will
have no effect on the wall motion of the affected
segment. Furthermore, in survivors of a ﬁrst AMI,
DSE allows effective risk stratiﬁcation on the basis of
the presence, severity, and extent the induced ische-
mia [62]. It is feasible and safe early after uncom-
plicated myocardial infarction and allows effective
risk stratiﬁcation on the basis of the presence,
severity, extent and timing of the induced ischemia.
In particular, the risk of death doubles in patients who
develop ischemia at high doses of Dobutamine
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ischemia at low doses (early stages of the dobutamine
stress echo protocol) [63].
Cardiac magnetic resonance imaging
The assessment of myocardial necrosis by the method
of late gadolinium enhancement (LGE) imaging is
based on essentially two premises, which were
initially established in experimental studies of acute
myocardial infarction. The loss of myocyte mem-
brane or sarcolemmal integrity during myocardial
ischemia is recognized to be tantamount to the loss
cell-viability, and myocardial viability. All available
evidence suggests that myocytes can not recover from
this disruption of the sarcolemma [64, 65]. The
extracellular contrast agents, once they can enter the
intra-cellular space, can cause signiﬁcantly higher
contrast enhancement than in normal, viable myo-
cardium, if sufﬁcient time is allowed for the contrast
agent to reach an infarct zone after contrast injection.
Post-infarct tissue remodeling leads subsequently to a
signiﬁcant increase of the interstitial space. Animal
studies comparing Gd-DTPA enhanced MR with the
standard of reference 99 m Tc-DTPA autoradiogra-
phy showed widely different distribution volumes for
extracellular contrast agents in viable and necrotic
myocardium, both in acute and chronic myocardial
infarction [66, 67].
The distribution volume for Gd-based contrast
agents in normal myocardium is on the order of 25%,
compared to 70% or higher in necrotic myocardium
[68]. However, the difference of contrast agent
concentrations between the different compartments
(infarct, viable tissue, blood) is not constant due to
complex wash-in and wash-out kinetics. Conse-
quently, the techniques used for LGE imaging have
to take into consideration both the time evolution of
contrast enhancement of infarcted, normal myocar-
dium, and possibly the blood pool, and also maximize
this contrast through the pulse sequence parameters
and contrast dosage.
Initial studies had focused on validating the LGE
technique in animal models of acute myocardial
infarction. A time delay of approximately 20 min
between contrast injection and LGE image acquisition
was considered optimal for the detection of myocar-
dial infarction and yielded good agreement with
histology [67]. Delivery of the contrast agent to the
infarct zone is generally limited by blood ﬂow to the
infarct zone for the ﬁrst couple of minutes after
contrast injections, in particular in the absence of
recanalization. Despite this, a more recent study by
the original pioneers of the LGE technique established
that a time delay as short as 5 min post injection may
be sufﬁcient for a reliable detection of acute myocar-
dial infarcts, provided the contrast settings for the
image acquisition are adjusted [69]. In a recent multi-
center trial with a Gd-based contrast agent in patients
with acute and chronic infarctions the authors reported
that images acquired at 10- and 30-min after contrast
injection appeared to yield equal performance for the
detection of MI [70]. LGE disappears as the contrast
agent is eliminated from the blood pool, with a half
time in the blood pool on the order of 30 min for the
Gd-based contrast agents.
Contrast delivery can be impaired during an early
phase by microvascular obstruction, which is a result
of the blockage of the microcirculation in the infarct
zone due to physical obstruction of capillaries by
leukocytes, compression of capillaries and hemor-
rhage. Microvascular obstruction is generally most
pronounced at the core of a myocardial infarct.
Microvascular obstruction has a clear signature in
MRI as a core zone in an infarct that does initially not
enhance after contrast injection, but is surrounded
within the LV wall by non-viable myocardium with
sufﬁcient up-take of contrast agent to show hyperen-
hancement [71, 72]. The initially dark infarct core
then slowly ﬁlls in with contrast over a couple of
minutes. A typical LGE image of a patient with
microvasvcular obstruction after a recent acute myo-
cardial infarction is illustrated in Fig. 1. The exact
mode of contrast delivery in areas with microvascular
obstruction remains poorly understood but may be
related to diffusive rather than convective transport of
the contrast agent to the infarct core. The hypoen-
hancement lasts for approximately 10 min or less
after injection of Gd-based contrast agents, and
eventually the core of the infarct also enhances
[73]. First pass perfusion imaging may be an even
more sensitive method to detect microvascular
obstruction [74].
Myocardial edema has been shown to accompany
acute myocardial infarction following cellular swell-
ing and increased intracellular osmolarity. The signal
intensity of T2-weighted MR techniques have been
14 Int J Cardiovasc Imaging (2011) 27:7–24
123shown to correlate with the amount of myocardial
water content in experimental infarcts and have
proven to reliably visualize myocardial edema in
AMI [75–79]. In patients with chronic myocardial
infarction (CMI) no increase in SI is exhibited in T2-
weighted imaging [80]. The extent of the myocardial
edema in AMI though not only delineates the
infarcted area itself, but also the threatened peri-
infarct regions the so-called ‘‘area at risk’’ [79, 81,
82]. Based on its high accuracy ([95%) T2 weighted
MR imaging is the current MR approach to identify
and differentiate acute from chronic myocardial
infarction [79]. It also allows visualizing the effect
of revascularization, as most of the area at risk will
subsequently become necrotic, if no revascularization
is performed. As the image quality of SE or FSE
based MR techniques may be subject to major
variation and these techniques also result in a
signiﬁcant time effort recent technical developments
further improve and push the application of T2
weighted techniques in infarction assessment [81].
A timely and reliable diagnosis of MI is required
for proper treatment of patients in the acute setting, to
improve the patients’ outcome and to reduce the rate
of re-events. A considerable number of patients,
though may experience silent MI without noticing
and thus during routine checkup there might be no
evidence of MI in serum enzymes tests or even ECG
[83, 84]. In a diabetic population in up to 28% of the
patients LGE may be present without any clinical
evidence of previous MI [85]. However, these
patients would also substantially beneﬁt from
Fig. 1 Example of a 76 year old male patient with an acute
myocardial infarction (STEMI) of the anterior wall after acute
PCI of the occluded LAD with stent implantation (pain-to-
balloon time 150 min.). a The water sensitive T2-STIR image
demonstrates the edema in the anterior wall (white arrows),
c the LGE images demonstrate an almost transmural myocar-
dial infarction (white arrows) with central MVO (asterisk).
This indicates almost no myocardial salvage after successful
revascularization of the LAD. b shows the T2* image at
TE = 15 ms and d the T2* imaging map of the T2* mapping.
The central dark area (white arrow) represents pixels with a
T2* decay\20 ms indicating postreperfusionhemorrhage
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patients with known history of MI. Especially subtle
silent subendocardial infarction may be missed by lab
testing, ECG or even nuclear medicine tests [86]. In
patients presenting with symptoms of acute MI the
delineation of possible previous MI is also of major
importance and may contribute to further patient
triage. Several recent clinical studies have indicated
the multi-faceted approach by CMR can characterize
the spectrum of disease in patients with acute
coronary syndromes with high accuracy. A resting
study that consists of myocardial perfusion, cine
function, and LGE performed in the emergency room
can detect acute coronary syndromes at a high
sensitivity and speciﬁcity [87]. The addition of T2-
weighted imaging of area-at-risk improves the spec-
iﬁcity to detecting acute coronary syndrome by
assessing the acuteness of the ischemic event [88].
Adding stress perfusion enhances the test’s sensitivity
[89] and has been shown to be a powerful risk
stratifying tool to adverse cardiac events within
12 months after hospital presentation [90].
Areas initially involved in acute myocardial
infarctions do undergo a steady process of change
in their composition within the ﬁrst days and weeks.
This process includes resorption and scar tissue
formation with possible ventricular remodeling that
may further deteriorate global cardiac function. In the
acute setting infarct areas consistently exhibit cell
necrosis as well as a considerable myocardial edema;
areas of microvascular obstruction (MVO or ‘‘no-
reﬂow’’-zones) resulting from capillary obstruction,
edema and endothelial swelling may also be present
and are found in a large percentage of ST-segment
elevating AMI. In the setting of chronic MI the
initially necrotic myocardium is replaced by scar
tissue formation with a large extracellular space and
less dense cell distribution than in normal myocar-
dium [91]. With the resorption process the size of the
infarcted area typically shows a *20–40% reduction
in the overall volume but also a reduction in its
transmural extent although there may be larger
variations [92–95]. These changes on the morphology
of the infarcted area as well as the change in its
functional and metabolic status provide the basics for
differentiation of acute from chronic by means of
non-invasive imaging modalities. Recent clinical
evidence indicates that detection of MVO has
important prognostic value beyond infarct size in
patients who suffered an acute MI [96]. O0Regan
et al. [97] examined 15 patients after acute PCI in
acute myocardial infarction using a T2* mapping
technique and demonstrated that patients with hem-
orrhage after revascularization had lower LVEF,
lower myocardial salvage [81] greater infarct size
and more MVO (Fig. 1).
Areas with wall motion abnormalities but less than
50% transmural hyperenhancement are generally
regarded as having a high likelihood for functional
recovery after revascularization [98, 99]. In these
areas the remaining myocardium is not necrotic, but
in a ‘‘stunned’’ or ‘‘hibernating’’ state. Stunned
myocardium is myocardium, which has suffered
from severe ischaemia, consequently stopped con-
tracting, but has not been irreversibly damaged.
Blood ﬂow to these areas has been restored by
revascularization. If this situation becomes chronic as
no revascularization has been performed, these areas
become hibernating, just preserving their cellular
integrity, but not contributing to cardiac function.
Low dose dobutamine CMR may be a better predictor
of recovery of function following revascularization
[100] mainly in patients with intermediate transmu-
rality of myocardial necrosis. But there are also
studies available, which show a better prediction of
functional recovery after revascularization proce-
dures by using the LGE technique compared to low
dose dobutamine stress [101]. Gutberlet et al. [101]
demonstrated in 20 patients examined before and
6 months after successful revascularization, that LGE
showed the best results for predicting functional
recovery compared to low-dose dobutamine stress,
wall thickness and also SPECT imaging. The com-
bination of LGE with dobutamine CMR may improve
the diagnostic accuracy [102] although this concept is
controversial [103].
Dysfunctional myocardium not uncommonly has
associated thrombus. A study by Srichi et al. showed
that CMR is more sensitive than either transthoracic
or transesophageal echocardiography for the detec-
tion of ventricular thrombus in patients with ischemic
heart disease [104]. Given the risk of embolization in
these patients, CMR has a distinct advantage over
other techniques.
Furthermore, CMR with the use of edema and
inﬂammation sensitive sequences and LGE allows for
the differential diagnosis of myocarditis [105, 106],
tako-tsubocardiomyopathy (TTC) [107–109] and
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all three can present with similar acute symptoms,
ECG-changes, focal wall motion abnormalities and
elevated troponin levels, but demonstrate in MRI
with different typical features. Acute MI demon-
strates with edema and typically subendocardial to
transmural LGE (Fig. 1), myocarditis also demon-
strates with edema but a usually subepicardial LGE
(Fig. 2) and TTC can also appear with edema, but no
LGE and shows usually total recovery of ventricular
function after a few weeks (Fig. 3).
In summary, CMR is well suited to detect wall
motion abnormalities (stunning, hibernation, necro-
sis), area at risk (with T2 imaging), irreversible
damage (necrosis, by LGE), microvascular obstruc-
tion (as an independent risk factor), and thrombus in a
single examination [74]. Ischemia imaging has no
role in patients with acute coronary syndromes but is
a strong component of the work up of patients
presenting with chest pain (Figs. 4, 5).
Cardiac CT
Cardiac CT has already been established as a highly
useful adjunct to percutaneous intervention [110].
With the development of high-speed CT systems,
cardiac CT is becoming a ﬁrst line diagnostic
modality in the evaluation of chest pain of unknown
origin. This includes atypical presentations of myo-
cardial infarction and presentations that do not result
in ECG changes.
Arterial phase imaging is mainly dedicated to
coronary CT angiography with identiﬁcation of
possible coronary artery stenoses of coronary plaque
formation. A detailed analysis of the myocardial
A T2-STIR    B T1-w PSIR late Gd-enh C T1-w IR-GRE LGE
oedema scar scar
Fig. 2 CMR of a 20 year old man with biopsy proven acute myocarditis. a Demonstrates the typical ﬁnding of a subepicardialedema
(white arrows) and LGE, b, c indicating acute myocardial inﬂammation and irreversible cell death
A  B  CD
acute 3 months follow up  LGE
Fig. 3 Cine CMR images of a 40 year old female patient
during diastole (a) and systole (b) acquired at acute phase of
takotsubocardiomyopathy (TTC) demonstrating apical
ballooning (black arrows) in the absence of LGE (c). A
repeated Cine CMR 3 months later (d) showed complete
normalization of systolic ventricular function
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123density can give more precise information on possible
myocardial perfusion deﬁcits and infarction (Fig. 1).
Kachenoura et al. found improved diagnostic accu-
racy for CCTA in a group of 84 patients when
myocardial perfusion was also assessed [111]. A
signiﬁcantly lower attenuation level of infarcted
myocardium (any age; acute and chronic) in com-
parison to normal myocardium has been observed
[112–115]. In regard to the differentiation of acute vs.
chronic infarctions, some studies showed a tendency
to lower attenuation of chronic infarctions compared
to acutely injured myocardium [113, 114] while
others could hardly tell a difference [112]. Inherent
differences in CT technology and injection protocols
may explain discrepant results. In the acute setting
the underlying principle of hypo-attenuation in arte-
rial phase cardiac CT is most likely related to a
decreased perfusion while the even lower densities in
a chronic infarct setting may be based in changes of
the myocardial wall texture with scar tissue develop-
ment and also possible fatty replacement [113].
Within recent years the principle of ‘‘delayed
enhancement’’ imaging as used in MRI has also been
systematically been evaluated in cardiac CT. In fact,
the principle of ‘‘delayed enhancement’’ has initially
been described based on CT imaging in the late 1970s
[116]. Recent animal studies have conﬁrmed the
ability to accurately evaluate acute and chronic
infarctions by means of this technique [117–119]
and conﬁrmed in patient studies [117, 120]. CT does
not allow to accurately differentiate acute from
chronic infarctions solely based on this feature. The
accuracy for detection and size of MI appears to be
roughly comparable to CMR [112].
Delayed enhancement imaging is realized 5–7 min
after injection in acute settings, and later for visual-
isation of a ﬁbrotic, chronic scar. Low kilovoltage
settings (80 kV for patients under 80 kg of weight,
100 kV above) are recommended to enhance iodine
attenuation and lower radiation dose delivery. Thick
MPR images of 5–8 mm are adequate to visualize
myocardium using short-axis, 2 and 4 chambers
views. Transmural infarction appears as hyperen-
hanced myocardium. A central hypoenhanced area,
surrounded by contrast enhancement (central core of
the infarction) may be observed. This feature corre-
sponds to the no-reﬂow phenomena, which is also
associated with poor recovery of the contractile
function. Compared to transmural enhancement, sub-
endocardial changes may be more difﬁcult to detect
due to similar contrast between the damaged myocar-
dium and left ventricular cavity, the latter being still
partially enhanced 10 min after iodine injection.
Delayed enhancement imaging seems more chal-
lenging is case of chronic MI when compared to
acute MI. Contrast uptake appears to be weaker
compared to acute myocardial infarction. Optimal
timing may be different from acute MI because of
difference of contrast distribution in case of ﬁbrosis:
there is at present time no recommendation for
Fig. 4 Example of acute MI due to occlusion of an obtuse
marginal artery [126]. First pass MSCT shows local hypoen-
hancement of the antero-lateral wall. This perfusion defect was
leading to ﬁnd the culprit lesion in a 3 vessel disease patient
Fig. 5 Post-angioplasty MSCT without reinjection of contrast
medium, showing transmuralantero-septal contrast uptake,
involving papillary muscle (asterisk). This ﬁnding predicts
poor recovery of the antero-septal wall
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123optimal visualisation of chronic scar. Thrombus
detection in the left ventricle may be facilitated by
delayed enhancement imaging, by a better differen-
tiation between enhanced left ventricle wall and non-
enhanced thrombus.
Recently, use of cardiac CT just after a coronary
angioplasty has been proposed, without needs for
reinjection of iodine. This procedure has been shown
to be safe and easy to perform. Intra-arterial iodine
injected during the angioplasty may be indeed also
used as a marker of myocardial damage (Fig. 2). The
ﬁrst study on this topic showed that the transmural
pattern of contrast uptake within the myocardium was
closely linked to absence of functional recovery
(absence of viability) using low-dose dobutamine
echocardiography for comparison [121]. In addition,
CTﬁndingswerefoundwellcorrelatedtoMRrealized
8 days after [122]. A third paper showed that trans-
mural damage observed just after coronary stenting
without reinjection of contrast was able to predict LV
remodelling or heart failure at 6 months [123].
It does appear possible to detect ischemia with CT
perfusion using adenosine perfusion [124, 125]. In
combination with delayed enhanced imaging, it may
be possible to provide a comprehensive evaluation for
coronary artery stenosis and its functional signiﬁ-
cance in concert with infarct imaging. Such an
approach has not yet been evaluated but may become
feasible as radiation dose decreases with more
modern CT technology.
Conclusions
ECG remains the ﬁrst line test for myocardial
infarction together with the use of biomarkers in the
acute setting.
Catheter based coronary angiography is used for
the diagnosis and treatment of acute coronary
syndrome. The role for non-invasive imaging in the
acute setting is in patients for which the diagnosis is
uncertain, for assessment of resulting mechanical
causes of heart failure and for risk assessment. Echo
because of its portability can offer critical informa-
tion very early in AMI.
PET has traditionally been regarded as the refer-
ence standard for myocardial viability. Its place
has been challenged recently by CMR, which can
detect smaller myocardial infarctions that can be
prognostically important with no radiation. Together
with its ability to detect ventricular thrombus, edema
and inﬂammation, CMR is a compelling alternative
test and furthermore, allows monitoring of revascu-
larization procedures0 success. Currently there exist
more software tools to quantitate and display scar
burden by PET but we can anticipate that this
advantage will rapidly evaporate since this is now a
focus of activity of software development. Intra-
cellular contrast agents currently under investigation
may more readily identify areas with reversible
ischemia by CMR.
Ischemia and infarct imaging by CT is now
becoming feasible with the latest generation CT
equipment. This technology needs to be assessed and
compared with standard tests. The combination of
coronary anatomy and myocardial abnormalities is
only possible by CMR and CT. Coronary anatomy
visualization is currently more robust with CT and
easier to obtain. We anticipate that myocardial
imaging with CT will be an active area of research
for the next few years.
In addition to accuracy, the costs of tests affect
their utilization. PET is relatively expensive in this
regard. Nevertheless, the bar has been raised by the
Centers for Medicare and Medicaid Services (CMS)
in the US for the acceptance of new technologies. In
order for a new test to be reimbursed by CMS, the test
needs to demonstrate that its use positively improves
patient outcomes particularly in the form of random-
ized controlled trials. There is currently the strongest
outcome data in the echo and nuclear imaging
literature although there is a growing body of
supporting literature for CMR. It is likely that most
countries will similarly require outcome data for
acceptance. Thus we anticipate that more outcome
studies will be a focus of future research.
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